Understanding how vaccines trigger immune responses against influenza neuraminidase.
Dynamics of the protective vaccine-induced human influenza neuraminidase B cell response
This study is looking at how vaccines help your body fight the flu by focusing on a specific part of the virus, and it aims to find ways to make better vaccines and treatments for everyone.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project ID | NIH-10468065 on NIH RePORTER |
What this research studies
This research investigates the immune response generated by vaccines against the neuraminidase protein of the influenza virus. It focuses on how the body produces antibodies that can effectively target this protein, which is crucial for developing better vaccines and treatments. By studying the mechanisms behind these immune responses, the research aims to enhance our understanding of how to protect against influenza infections more effectively. Patients may benefit from insights that could lead to improved vaccine formulations and therapeutic options.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older who are interested in influenza vaccination and its effects on immune responses.
Not a fit: Patients who are not adults or those with specific contraindications to influenza vaccination may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective vaccines and treatments for influenza, reducing the severity and duration of infections.
How similar studies have performed: Previous research has shown that targeting neuraminidase can provide protective effects against influenza, indicating that this approach has potential for success.
Where this research is happening
Birmingham, United States
- University of Alabama at Birmingham — Birmingham, United States (Active)
Researchers
- Principal investigator: Kobie, James J — University of Alabama at Birmingham
- Study coordinator: Kobie, James J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.